PF-4856884 / Pfizer - LARVOL DELTA

Angiopoietin inhibitors: A review on targeting tumor angiogenesis. (PubMed, Eur J Pharmacol) - "Drugs studied in the article are selective as well as non-selective inhibitors of angiopoietin 2 like Trebananib (AMG 386), AMG 780, REGN 910, CVX 060, MEDI 3617 and dual inhibitors of angiopoietin 2 and VEGF like Vanucizumab and RG7716. The angiopoietin inhibitors show promising results alone and in combination with VEGF inhibitors in various malignancies."

Journal • Review • Immunology • Inflammation • Oncology

Phase Ib safety trial of CVX-060, an intravenous humanized monoclonal CovX body inhibiting angiopoietin 2 (Ang-2), with sunitinib (ASCO 2012) - Presentation time: Sat, Jun 2, 1:15 PM - 5:15 PM; Anticipated presentation at ASCO 2012

Anticipated P1 data presentation • Oncology • Renal Cell Carcinoma

Phase Ib safety trial of CVX-060, an intravenous humanized monoclonal CovX body inhibiting angiopoietin 2 (Ang-2), with sunitinib (ASCO 2012) - Presentation time: Saturday June 2, 1:15 PM to 5:15 PM; P1b, N=34; Of the 34 patients, 24 (71%) remained on study ≥ 8 weeks and 2 patients continue on treatment ≥ 9 months; Anti-drug antibodies were seen in 16 patients at low titers without effects on PK or safety

P1b data • Oncology

PF-04856884 (CVX-060) in combination with axitinib in patients with previously treated metastatic renal cell carcinoma (clinicaltrials.gov) - P2, N=165; Recruiting; Completion date: Mar ‘15 -> Dec ’13

Completion date • Oncology • Renal Cell Carcinoma

Phase Ib safety trial of CVX-060, an intravenous humanized monoclonal CovX body inhibiting angiopoietin 2 (Ang-2), with axitinib in patients with previously treated metastatic renal cell cancer (RCC) (ASCO 2013) - Presentation time: Monday, Jun 3, 8:00 AM - 11:45 AM; Abstract #2533; P1, N=18; NCT01441414; Sponsor: Pfizer; "One pt had Grade 2 venous thrombosis unrelated to either treatment, Due to the reported TEE, PF-04856884 was reduced to 10 mg/kg in pts remaining on study and enrollment to Part II was not initiated. No significant PK interaction was observed"

P1 data • Oncology • Renal Cell Carcinoma